Spotlight Finalizes Memcine Acquisition

Spotlight Innovation announced Monday that it has finalized its acquisition of Memcine Pharmaceuticals.

The deal gives Spotlight access to Memcine’s development-stage Immunoplex vaccine platform technology, which capitalizes on the body’s natural targeting system when administering vaccine components to white blood cells.

Spotlight President and CEO Chris Grunewald says the platform shows promise for broad applicability in infectious disease treatment and oncology immunotherapy.

West Des Moines, Iowa-based Spotlight Innovation focuses on working with or acquiring early-stage healthcare companies.

Memcine Pharmaceuticals is located at the University of Iowa Research Park in Coralville, Iowa, and has entered into a licensing agreement with the university. — Jason Scott